Transglutaminase 2 as an independent prognostic marker for survival of patients with non-adenocarcinoma subtype of non-small cell lung cancer

Chang-Min Choi†, Se-Jin Jang†, Seong-Yeol Park, Yong-Bock Choi, Jae-Heon Jeong, Dae-Seok Kim, Hyun-Kyoung Kim, Kang-Seo Park, Byung-Ho Nam, Hyeong-Ryul Kim, Korean Thoracic Oncology Research Group (KTORG), Soo-Youl Kim and Kyeong-Man Hong

Abstract

**Background:** Expression of transglutaminase 2 (TGase 2) is related to invasion and resistance to chemotherapeutic agents in several cancer cells. However, there has been only limited clinical validation of TGase 2 as an independent prognostic marker in cancer.

**Methods:** The significance of TGase 2 expression as an invasive/migratory factor was addressed by *in vitro* assays employing down-regulation of TGase 2. TGase 2 expression as a prognostic indicator was assessed in 429 Korean patients with early-stage non-small cell lung cancer (NSCLC) by immunohistochemical staining.

**Results:** TGase 2 expression increased the invasive and migratory properties of NSCLC cells *in vitro*, which might be related to the induction of MMP-9. In the analysis of the immunohistochemical staining, TGase 2 expression in tumors was significantly correlated with recurrence in NSCLC (p = 0.005) or in the non-adenocarcinoma subtype (p = 0.031). Additionally, a multivariate analysis also showed a significant correlation between strong TGase 2 expression and shorter disease-free survival (DFS) in NSCLC (p = 0.029 and HR = 1.554) and in the non-adenocarcinoma subtype (p = 0.030 and HR = 2.184). However, the correlation in the adenocarcinoma subtype was not significant.

**Conclusions:** TGase 2 expression was significantly correlated with recurrence and shorter DFS in NSCLC, especially in the non-adenocarcinoma subtype including squamous cell carcinoma.

Background

Lung cancer is the leading cause of cancer-related death, accounting for approximately 29% of all cases (*Cancer Stat Fact Sheets*, http://www.seer.cancer.gov); approximately 85% of lung cancer cases are non-small cell lung cancer (NSCLC). There are several different subtypes of NSCLC, among which are adenocarcinoma and squamous cell cancer. Currently, the NSCLC subtypes are regarded as a single disease, however, the adenocarcinoma and non-adenocarcinoma subtypes are regarded as being separate entities, owing to their different responses to recently developed agents such as pemetrexed, gefitinib, bevacizumab, and crizotinib, which are more effective in adenocarcinoma [1-3]. Accordingly, identification of the molecular differences between these tumor types will have a significant impact on the design of novel therapies that can improve treatment outcomes.

Transglutaminase 2 (TGase 2) is a multifunctional protein that can bind and hydrolyze GTP as well as catalyze covalent cross-links [4]. The biological role of TGase 2 in the development of resistance to cisplatin and doxorubicin in several cancer cells has drawn considerable attention [5-9]. Another biological role of
TGase 2, this one in cancer metastasis and invasion, was reported for breast, pancreatic, and ovarian cancers [10-13]. However, the role of TGase 2 expression as an independent prognostic factor has not been well elucidated, except for a study on ovarian cancer [11]. Moreover, the possibility that TGase 2 has different roles in different subtypes of any cancer has never been suggested. Accordingly, in the present study, after first testing the biological role of TGase 2 in invasion and migration with NSCLC cell lines, its role as a prognostic indicator in NSCLC was investigated in an immunohistochemical study on early-stage NSCLC tissues.

Materials and methods

Cell lines

Human squamous lung cancer cell lines H1703 and HCC-95 were obtained from the Korean Cell Line Bank and maintained in RPMI 1640 supplemented with 10% fetal bovine serum (Thermo Fisher Scientific Hyclone, Logan, UT), 1 mM sodium pyruvate, and 100 U/mL penicillin-streptomycin at 37°C in a humidified 5% CO2 incubator.

Scratch cell migration assay

Parental cells or cells transfected with control or small interfering RNAs (siRNAs) targeting TGase 2 were grown to confluence, at which time they were scratched with a pipette tip. Cell lines not treated with siRNA were starved by incubation overnight in serum-free medium. The cultures were rinsed to remove detached cells and then incubated for 24-48 h. After incubation, the cells were fixed and visualized by light microscopy. These assays were performed three times.

Matrigel cell invasion assay

The invasive behavior of cells was determined in vitro using BioCoat Matrigel Invasions Chamber (BD Biosciences, Bedford, MA) inserts. The cells were trypsinized, and the resulting cell pellets were resuspended in serum-free medium at a final concentration of 1 × 10^5 cells, after which 500 μL of suspended cells was added to the insert with 750 μL of complete medium. After 24 or 48 h incubation, the cells that passed through the filter to the underside of the membrane were stained and counted under a light microscope. Ten fields of cells were counted for each well, and the mean number of cells per field was calculated. Each experiment was performed in triplicate and repeated at least two times.

Transfection

TGase 2 was knocked down by introducing an siRNA duplex targeting human TGM2 mRNA (5’-AAG AGC GAG AUG AUC UGG AAC-3’) into cells using Fugene 6 (Roche, Mannheim, Germany) according to the manufacturer’s instructions. Briefly, cells were seeded at a density of 3 × 10^5 per well in a six-well plate. When the cells reached about 60% confluence, 400 μL of an siRNA-Fugene 6 mixture was added, and the cells were incubated for 48 h in a 5%CO2 incubator.

Western blot analysis

Equal amounts of each cell lysate were electrophoresed on sodium dodecyl sulfate-polyacrylamide gels, after which resolved proteins were transferred to polyvinylidene difluoride membranes. The membranes were incubated with various primary antibodies diluted in TBST (20 mM Tris, 134 mM NaCl, 0.02% Tween 20). The primary antibodies were then detected with horseradish peroxidase-conjugated secondary antibodies followed by exposure to an enhanced chemiluminescence reagent. The antibodies for MMP-9, MMP-2 and Vimentin were purchased from Santa Cruz Biotechnology (Santa Cruz, California); those for E-cadherin and b-actin were obtained from Abcam (Cambridge, MA).

Gelatin zymography

MMP-9 activity in the cultured cells was measured using gelatin-gel zymography. The ten-fold-concentrated culture medium was electrophoretically resolved by 7.5% SDS-PAGE containing 0.1% gelatin under the non-reducing condition. The gel was washed in 2.5% Triton X-100 for 30 min to remove SDS and incubated overnight at 37°C in 50 mM Tris-Cl, pH 7.5, and 5 mM CaCl2. After Coomassie blue staining and destaining of the gel, the MMP-9 activity was detected as a clear band on a dark blue background.

NSCLC cancer tissues and other human tissues

A total of 429 NSCLC cases for which surgery had been performed at the Asan Medical Center (Seoul, Korea) between 2000 and 2003 were selected from the archives of the Department of Pathology, and tissue arrays were prepared. The use of relevant human archival tissues was approved by the Institutional Review Board. All available histological slides, which had been routinely stained with hematoxylin and eosin (H&E), were reviewed. As controls, a variety of human tissue array sections (BB6, CCA3, CC4, CSA3, CBA3 and CDA2), purchased from SuperBioChip Laboratories (http://www.tissue-array.com), were used.

Immunohistochemical staining of TGase 2 in NSCLC

Immunohistochemical staining was performed using an Ultravision LP Detection kit (Lab Vision, USA). The tissue sections were deparaffinized with xylene, and antigen retrieval was accomplished by autoclaving the slides in 10 mM Tris (pH 9.0) and 1 mM EDTA for 15 min. After fixing in 95% ethanol, the slides were treated with
3% hydrogen peroxide, incubated with Ultra V block solution for 15 min, and then incubated with anti-TGase 2 primary antibody (NeoMarkers, Fremont, CA) at a dilution of 1:200 for 1 h at room temperature. After washing in TBST, the slides were treated with primary antibody enhancer for 10 min and then incubated with HRP-conjugated secondary antibody for 15 min. The slides were then washed with TBST, incubated with DAB chromogen, and counterstained with Mayer’s Hematoxylin (Dako Cytomation, Glostrup, Denmark). Negative controls, from which the primary antibody had been omitted, were run in parallel. Immunostaining was graded semi-quantitatively, considering both staining intensity and the percentage of positive tumor cells, by two study pathologists blinded to the clinicopathologic variables. The staining intensity was scored on a 0- to-3 scale: 0, no staining of cancer cells; 1, weak staining; 2, moderate staining; 3, strong staining. Also, the percentage of stained tumor cells was scored on a 0- to-3 scale: 0, <10%; 1, 10%-49%; 2, 50%-75%; 3, >75%. The two scores were multiplied, and TGase 2 expression was defined as negative, if the product was 0; intermediate, if the product was 1-3; and strong, if the product was 4 or more.

Expression of TGase 2 was found in cells of normal structure, specifically in smooth muscle and blood vessel endothelial cells. However, there was no such expression in alveolar or bronchial epithelial cells.

Statistical analysis
The Chi-square test was used to examine differences in TGase 2 immunoreactivity among the groups. The Kaplan-Meier method was employed to estimate survival distributions, and the survival curves were compared using the log-rank test. Values of p < 0.05 were considered statistically significant.

For the purpose of determining associations between TGase 2 over-expression and clinicopathologic variables, a Chi-square or Fisher’s exact test was applied. The Cox proportional hazard regression model was employed for univariate and multivariate analyses of the relationship between DFS and clinicopathologic variables or TGase 2 expression. In the multivariate analyses, the variables T-stage, N-stage and histologic type were included as co-variates. In analyses of the non-adenocarcinoma subtype, clinical stage, histologic type and differentiation status were considered as co-variates. All of the statistical analyses were performed using SPSS software (version 18).

Results
The question of whether TGase 2 expression confers a metastatic phenotype on lung cancer cells was addressed using two NSCLC cell lines: H1703 and HCC-95. TGase 2 was expressed at high levels in the H1703 cells, but was barely detectable in the HCC-95 cells, as determined by Western blot analysis and reverse transcription-polymerase chain reaction (RT-PCR) (Additional File 1, Figure S1A). RT-PCR and Western blot analysis showed that TGM2 siRNA reduced TGase 2 expression in the H1703 cells (Additional File 1, Figure S1A). In addition, TGase 2 down-regulation reduced nuclear factor κB (NF-κB) activity in the H1703 cells (Additional File 1, Figure S1B), as we had previously demonstrated for H1299 [9].

Because increased cell motility and invasion are important features of metastatic cancer cells, we compared the H1703 and HCC-95 cells for invasiveness, employing a Matrigel invasion assay. As shown in Figures 1A and 1B, the H1703 cells exhibited greater invasiveness than the HCC-95 cells, suggesting that invasiveness might be related to TGase 2-expression levels in NSCLC. To further investigate the role of TGase 2, we transiently transfected H1703 cells with TGM2 siRNA to knock down the TGase 2 level. Notably, siRNA-mediated TGase 2 knockdown significantly reduced the invasiveness of the H1703 cells (Figures 1C and 1D). H1703 cells exhibited greater migration than the HCC-95 cells (Figure 1E-1F), and knockdown of TGase 2 by siRNA also reduced the migration of H1703 (Figure 1G-1H).

Further experiments concerning the relationships between TGase 2 expression and MMPs or EMT markers were performed, and it was found that TGase 2 down-regulation by TGM2 siRNA is related to down-regulation of MMP-9 but not of MMP-2 (Additional File 2, Figure S2), suggesting that TGase 2’s role in invasion and migration might be via the regulation of MMP-9. This is consistent with the previous result for epidermoid carcinoma, a skin cancer [14]. However, in ovarian cancer, MMP-2 rather than MMP-9 regulation by TGase 2 has been reported [13], indicating that different MMPs are regulated by TGase 2 in different types of cancer. The levels of epithelial-mesenchymal transition (EMT) markers such as Vimentin and E-cadherin were not changed by down-regulation of TGase 2 in NCI-H1703 cells (Additional File 2, Figure S2).

To determine the importance of TGase 2 as a prognostic factor in NSCLC cancer patients, we immunostained tissue arrays collected from Korean patients with early-stage NSCLC (Figure 2). Data on the 429 patients are listed in Table 1. All of the patients had undergone curative surgical resection by lobectomy (74.7%), pneumonectomy (16.4%), or bilobectomy (7.5%). About 51.5% of patients were stage I; 23.8% stage II, and 24.7% stage III (Table 1). The median follow-up was 62 months, in a 26-81 month range. The post-resection recurrence rate was about 40%. Histologically, strong TGase 2 expression was also detected in smooth muscle
Figure 1 Tgase 2 expression is associated with increased invasion or migration of NSCLC cells. The levels of invasiveness for the H1703 and HCC-95 cells were compared in a Matrigel invasion assay system (A and B). Representative fields of cells that migrated through the Matrigel to the underside of the membrane were either photographed (A) or counted randomly in 10 fields, with the average numbers of invading cells (±s.d.) plotted (B). Transient transfection of TGM2 siRNA decreased the invasiveness for H1703, as shown in the representative fields of cells photographed (C) and the average numbers of invading cells plotted (D). Compared with the HCC-95 cells (E), the cell migration was higher in NCI-H1703 cells having a higher level of Tgase 2 (F). The migration was reduced by the treatment of NCI-H1703 with TGM2 siRNA and the resultant down-regulation of Tgase 2 (G and H). The cell migration status was photographed after the indicated time period.
and endothelial cells. Of the 429 NSCLC tissue samples, 93 (21.7%) showed intermediate TGase 2-immunopositivity and 88 (20.5%), strong TGase 2-immunopositivity (Table 2).

A comparative analysis of the TGase 2 expression and clinicopathologic parameters in the 429 NSCLC cases (Table 2) showed that TGase 2 levels were significantly higher in adenocarcinoma than in squamous cell carcinoma (p < 0.001), in females than in males (p < 0.001), and in nonsmokers than in smokers (p < 0.001). TGase 2 expression was also significantly correlated with T-stage (p = 0.037), but not with pathologic differentiation (p = 0.474) or nodal status (p = 0.414), as shown in Table 2.
TGase 2 expression was significantly associated also with recurrence rate in the operable early-stage NSCLC cases examined (p = 0.005), as shown in Table 2. Notably, TGase 2 expression was significantly related to recurrence in the male (p = 0.011) and non-adenocarcinoma (p = 0.031) subgroups. By contrast, TGase 2 expression in the adenocarcinoma (p = 0.512) and female (p = 0.672) subgroups did not show any significant association with NSCLC recurrence. In a Kaplan-Meier plot of the total NSCLC patient population or of patients with the non-adenocarcinoma subtype, strong TGase 2 expression was correlated with shorter DFS (p = 0.011 for NSCLC, and p = 0.014 for the non-adenocarcinoma subtype by log rank test) (Figure 3). Squamous cell carcinoma was the major histologic type in the non-adenocarcinoma subtype of NSCLC. But other histologic types, including large cell carcinoma, adenosquamous cell carcinoma, and mucoepidermoid carcinoma, also were included in the analysis (Table 2).

In a univariate analysis (Table 3), DFS was significantly related to strong TGase 2 expression (p = 0.011) as well as the clinicopathologic variables including histologic type (p = 0.044), T-stage (p = 0.044), and N-stage (p < 0.001). In a multivariate analysis considering T-stage, N-stage, and histological subtype as co-variables using Cox’s proportional hazard regression model, TGase 2 expression was significantly related to shorter DFS (p = 0.029, and HR = 1.554, Table 3).

In the non-adenocarcinoma subtype, strong TGase 2 expression also was significantly associated with shorter DFS (p = 0.016, Table 1). Moreover, a multivariate analysis on the non-adenocarcinoma subtype considering histologic type, differentiation, and clinical stage as co-variables, also showed strong TGase 2 expression to be significantly correlated with shorter DFS (p = 0.030, HR = 2.184), as indicated in Additional File 3, Table S1. In the male NSCLC subgroups, strong TGase 2 expression was significantly related to shorter DFS (p = 0.024, data not shown), but the association, according to the multivariate analysis, was not significant.

**Table 1 Clinicopathologic characteristics of patients with NSCLC who had undergone complete resection**

| Variables                              | No. of subjects | (n = 429) |
|----------------------------------------|-----------------|-----------|
| Gender                                 |                 |           |
| Male                                   | 324 (75.5%)     |           |
| Female                                 | 105 (24.5%)     |           |
| Age (median, years)                    | 62 (range: 26-81)|           |
| Tumor size (median, cm)                | 3.8 (range: 0.8-20) |       |
| Type of surgical resection*            |                 |           |
| Pneumonectomy                          | 70 (16.4%)      |           |
| Bilobectomy                            | 32 (7.5%)       |           |
| Lobectomy                              | 319 (74.7%)     |           |
| Limited resection                      | 6 (1.4%)        |           |
| Clinical stage                         |                 |           |
| I                                      | 221 (51.5%)     |           |
| II                                     | 102 (23.8%)     |           |
| III                                    | 106 (24.7%)     |           |
| Adjuvant therapy**                     |                 |           |
| Chemotherapy only                      | 68 (15.9%)      |           |
| Radiotherapy only                      | 104 (24.2%)     |           |
| Neither                                | 184 (42.9%)     |           |
| Both                                   | 71 (16.6%)      |           |
| Median follow-up period (mean ± SD, months) | 65.8 (56.3 ± 33.9) |       |
| Recurrent cases (recurrence rate)      | 170 (39.6%)     |           |

* Information on the type of surgical resection was not available in two cases.  
** Information on radiotherapy was not available in two of the cases treated with chemotherapy.

**Discussion**

Previous reports [5,9] have posited cisplatin- and doxorubicin-resistance roles for TGase 2 in NSCLC cells. In the present study, we showed that TGase 2 down-regulation in lung cancer cells inhibited their invasive and migratory properties via the regulation of MMP-9. In immunohistochemical staining with Korean early-stage NSCLC tissues, strong TGase 2-positive cases had significantly higher rates of recurrence than TGase 2-negative cases (p = 0.005), and shorter DFS (p = 0.011). Moreover, this correlation was statistically significant in a multivariate analysis (p = 0.029), suggesting that TGase 2 is an independent prognostic marker for early-stage NSCLC survival.

The role of TGase 2 as an independent prognostic factor in surgically curative early-stage cancers appears to be evident in NSCLC. However, the role of TGase 2 in whole NSCLC cases is not as strong as in ovarian cancer [11]. In ovarian cancer, the correlation between survival and TGase 2 expression was shown to be statistically significant in a study of only 93 patients [11]. When we analyzed an identical number of the present NSCLC population, the association between TGase 2 expression and survival was not statistically significant. This suggests that TGase 2 might have a correlation with survival only in some subgroup(s) of NSCLC. To address this, we analyzed the correlation in different NSCLC subpopulations according to histologic type, gender, and smoking history. In the analysis, the association was significant in the male subgroup and non-adenocarcinoma subtype, but not in the female subgroup or in the adenocarcinoma subtype. In a multivariate analysis of the non-adenocarcinoma subtype, a significant association between TGase 2 expression and DFS was found, suggesting that TGase 2 expression is a prognostic marker.
only in the non-adenocarcinoma subtype including squamous cell carcinoma.

Until recently, the histologic subtyping of NSCLC was not clinically or therapeutically important. However, the adenocarcinoma and non-adenocarcinoma subtypes of NSCLC were suspected as separate entities, owing to the preferential responses to recently developed agents in adenocarcinoma [1-3]. This has encouraged research of new targets in adenocarcinoma NSCLC, and revisits the importance of subtyping notOtherwise-specified

Table 2 Correlation of TGase 2 overexpression with clinicopathologic variables in patients with resectable early-stage NSCLC

| Variables                  | Total number | TGase 2 expression | p-value |
|----------------------------|--------------|--------------------|---------|
|                            |              | Negative           | Intermediate | Strong |
| Histology                  |              |                    |           |        |
| Adenocarcinoma             | 193 (45)     | 74 (38)            | 58 (30)   | 61 (32) | <0.001 |
| Squamous carcinoma         | 198 (46)     | 155 (78)           | 26 (13)   | 17 (9)  |
| Others*                    | 38 (9)       | 19 (50)            | 9 (24)    | 10 (26) |
| Differentiation**          |              |                    |           |        |
| Well                       | 61 (18)      | 41 (67)            | 11 (18)   | 9 (15)  | 0.474 |
| Moderate                   | 200 (58)     | 122 (61)           | 41 (21)   | 37 (19) |
| Poorly                     | 87 (25)      | 47 (54)            | 18 (21)   | 22 (25) |
| Gender                     |              |                    |           |        |
| Male                       | 324 (76)     | 206 (64)           | 58 (18)   | 60 (19) | <0.001 |
| Female                     | 105 (24)     | 42 (40)            | 35 (33)   | 28 (27) |
| Smoking                    |              |                    |           |        |
| Nonsmoker                  | 113 (26)     | 44 (39)            | 35 (31)   | 34 (30) | <0.001 |
| Ex-smoker                  | 120 (28)     | 86 (72)            | 15 (13)   | 19 (16) |
| Current Smoker             | 196 (46)     | 118 (60)           | 43 (22)   | 35 (18) |
| T-stage***                 |              |                    |           |        |
| 1                          | 81 (19)      | 40 (50)            | 16 (20)   | 25 (31) | 0.037 |
| 2                          | 277 (65)     | 161 (58)           | 67 (24)   | 49 (18) |
| 3-4                        | 70 (16)      | 47 (67)            | 10 (14)   | 13 (19) |
| N-stage                    |              |                    |           |        |
| 0                          | 257 (60)     | 148 (58)           | 55 (21)   | 54 (21) | 0.414 |
| 1                          | 93 (22)      | 53 (57)            | 17 (18)   | 23 (25) |
| 2-3                        | 79 (18)      | 47 (60)            | 21 (27)   | 11 (14) |
| Recurrence event           |              |                    |           |        |
| No                         | 259 (60)     | 165 (64)           | 52 (20)   | 42 (16) | 0.005 |
| Yes                        | 170 (40)     | 83 (49)            | 41 (24)   | 46 (27) |
| Recurrence in male patients|              |                    |           |        |
| No                         | 203 (47)     | 141 (69)           | 33 (16)   | 29 (14) | 0.011 |
| Yes                        | 121 (28)     | 65 (54)            | 25 (21)   | 31 (26) |
| Recurrence in female patients|            |                    |           |        |
| No                         | 56 (53)      | 24 (42)            | 19 (34)   | 13 (23) | 0.672 |
| Yes                        | 49 (47)      | 18 (37)            | 16 (33)   | 15 (31) |
| Recurrence in patients with adenocarcinoma| | | | | |
| No                         | 102 (53)     | 43 (42)            | 29 (28)   | 30 (29) | 0.512 |
| Yes                        | 91 (47)      | 31 (34)            | 29 (32)   | 31 (34) |
| Recurrence in patients with non-adenocarcinoma| | | | | |
| No                         | 157 (67)     | 122 (78)           | 23 (15)   | 12 (8)  | 0.031 |
| Yes                        | 79 (33)      | 52 (66)            | 12 (15)   | 15 (19) |

The significance was tested with Chi-square or Fisher's exact tests (p). The percentages for the variables are shown within parentheses.

*Large cell lung cancer (13), adenosquamous carcinoma (9), mucopidermoid carcinoma (8), sarcomatoid carcinoma (3), Pleomorphic carcinoma (2), lymphepithelioma-like carcinoma (1), adenoid cystic carcinoma (1), and basaloid cell carcinoma (1)

**No information on the pathological differentiation status was available in 81 cases.

***No information on the T-stage was available in 81 cases.
**Figure 3** Kaplan-Meier plot of DFS according to different levels of TGase 2 expression in patients in the entire NSCLC population (A) or in the non-adenocarcinoma subtype (B). For analysis of the immunohistochemical staining, the weak and intermediate TGase 2-expression groups were combined into an intermediate group. The DFS of the patients with strong TGase 2 expression (red) was significantly shorter (* and **) than that of the TGase 2-negative patients (blue) in both groups (x-axis: months after surgery; y-axis: DFS probability).

**Table 3** Univariate and multivariate analyses of relationship between DFS and TGase 2 expression or clinicopathologic variables by Cox proportional hazard regression model (n = 429)

| Variable                | Univariate analysis | Multivariate analysis |
|-------------------------|---------------------|-----------------------|
|                         | Hazard ratio | 95% CI    | p-value | Hazard ratio | 95% CI    | p-value |
| Age                     | 1.001       | 0.986-1.016 | 0.889   |             |           |         |
| Gender                  |             |           |         |             |           |         |
| Male                    | 1           | 1         |         |             |           |         |
| Female                  | 1.107       | 0.794-1.542 | 0.549   |             |           |         |
| Histology               |             |           |         |             |           |         |
| Adenocarcinoma          |             |           |         |             |           |         |
| Male                    | 0.718       | 0.521-0.991 | 0.044   | 0.701       | 0.487-1.008 | 0.056   |
| Female                  | 1.200       | 0.705-2.042 | 0.501   | 1.214       | 0.710-2.076 | 0.478   |
| Squamous carcinoma      |             |           |         |             |           |         |
| Male                    | 0.862-2.354 | 0.168     |         |             |           |         |
| Female                  | 0.977-2.955 | 0.061     |         |             |           |         |
| Poorly                  | 1.424       |           |         |             |           |         |
| Differentiation         |             |           |         |             |           |         |
| Well                    | 1           | 1         |         |             |           |         |
| Moderate                |             |           |         |             |           |         |
| Poorly                  | 1.699       | 0.977-2.955 | 0.061   |             |           |         |
| Smoking status          |             |           |         |             |           |         |
| Non-smoker              | 1.060       | 0.720-1.560 | 0.769   |             |           |         |
| Ex-smoker               | 0.766       | 0.535-1.096 | 0.144   |             |           |         |
| Current smoker          | 1.424       | 1.0879-1.992 | 0.180   | 1.463       | 0.962-2.224 | 0.069   |
| T-Stage                 |             |           |         |             |           |         |
| 1                       |             |           |         |             |           |         |
| 2                       | 1.323       | 1.0879-1.992 | 0.180   | 1.463       | 0.962-2.224 | 0.069   |
| 3-4                     | 1.898       | 1.143-3.150 | 0.013   | 2.209       | 1.308-3.731 | 0.003   |
| N-Stage                 |             |           |         |             |           |         |
| 0                       |             |           |         |             |           |         |
| 1                       | 1.613       | 1.116-2.330 | 0.011   | 1.625       | 1.118-2.363 | 0.011   |
| 2-3                     | 2.121       | 1.459-3.084 | <0.001  | 2.074       | 1.422-3.025 | <0.001  |
| TGase 2 expression      |             |           |         |             |           |         |
| Negative                | 1.230       | 0.846-1.789 | 0.277   | 1.111       | 0.752-1.642 | 0.597   |
| Intermediate            | 1.595       | 1.112-2.287 | 0.011   | 1.554       | 1.046-2.311 | 0.029   |
| Strong                  | 1.230       | 0.846-1.789 | 0.277   | 1.111       | 0.752-1.642 | 0.597   |

In the multivariate analysis, variables including histology, T-stage and N-stage (those showing p < 0.10 in the univariate analysis) were considered.
bronchial biopsy specimens [15]. However, the molecular targets in the non-adenocarcinoma subtype have not been well studied, and new targeted drug development in this subtype has been quite limited. The difference in therapeutic response might be related to the origin of cell types and to the subsequent molecular differences in the course of cancer progression. In this context, our finding of a specific association between TGase 2 expression and DFS in the non-adenocarcinoma subtype might point to TGase 2 as a molecular target in the non-adenocarcinoma subtype of NSCLC, which includes squamous cell carcinoma.

The enhanced migratory or invasive properties of TGase 2 expression might be related to the high binding affinity of TGase 2 to cell adhesion molecules such as fibronectin and integrin [16-19]. The interaction between TGase 2 and cell adhesion molecules in relation to invasion and metastasis has been further investigated in breast and ovarian cancers [12,13]. TGase 2-mediated induction of EMT along with the over-expression of various transcription repressors such as Snail, Zeb1, Zeb2 and Twist1 also has been reported, suggesting that TGase 2 is a key molecule involved in metastasis via EMT [20]. However, in the present study, TGase 2 down-regulation in a squamous lung cancer cell line did not affect the level of EMT markers, suggesting the induction of NSCLC invasion might not be via EMT pathway. In addition, high expression of TGase 2 in NSCLC can enhance the apoptotic threshold via the induction of NF-κB, enabling survival of migrating cancer cells in the face of harsh micro-environmental stresses during the metastatic process. In the process, intracellular TGase 2 cross-links the inhibitory subunit α of nuclear factor (I-κBα), thus releasing NF-κB from its binding with I-κBα [21,22]. Although the invasive property was shown to be related to TGase 2 expression in squamous NSCLC cell lines via the regulation of MMP-9 in the present study, the reason that TGase 2 expression has an impact on survival or recurrence remains to be revealed.

**Conclusion**

This study showed a significant association between TGase 2 expression and recurrence or shorter DFS, implicating TGase 2 as a prognostic marker in non-adenocarcinoma NSCLC. Recurrence or shorter survival in cases with higher TGase 2 expression might be related to the fact that TGase 2 over-expression enhances the invasive and migratory properties of NSCLC cells. The present study might also suggest that TGase 2 is a molecular target for the treatment of the non-adenocarcinoma subtype, which might be of importance with regard to the clinical application of TGase 2 inhibitor therapy.

**Additional material**

**Additional File 1: Figure S1. TGase 2 and NF-κB expression in NSCLC cells.** H1703 showed higher level of TGM2 or TGase 2 than HCC-95, and down-regulation of TGM2 in the H1703 cell decreased NF-κB activity.

**Additional file 2: Figure S2. The relationship between TGase 2 expression and MMP-9 activity in squamous lung cancer cell lines.** Relationship between TGase 2 expression and matrix metalloproteinases (MMPs) or epithelial mesenchymal transition (EMT) markers was tested, and it was shown that only MMP-9 has a positive correlation with TGase 2 expression, suggesting that TGase 2’s role in invasion and migration might be via the regulation of MMP-9.

**Additional file 3: Table S1. Univariate and multivariate analyses of relationship between DFS and clinicopathologic variables or TGase 2 expression by Cox proportional hazard regression model in non-adenocarcinoma patients with NSCLC.** A multivariate analysis on the non-adenocarcinoma subtype considering histologic type, differentiation, and clinical stage as co-variables, also showed strong TGase 2 expression to be significantly correlated with shorter DFS.

**Acknowledgements**

This work was supported by research grants (grant nos. 0810240 and 1110130) from the National Cancer Center, Korea. CCM, SJJ, HRK and KMH are the members of KTORG. We thank Dr. Chung JH at the Department of Pathology, Seoul National University College of Medicine, for her critical comments.

**Author details**

1. Department of Pulmonary and Critical Care Medicine, Asan Medical Center, College of Medicine, University of Ulsan, 388-1 Pungnap-2 Dong, SongPa-Gu, Seoul 138-736, Korea. 2. Department of Pathology, Asan Medical Center, College of Medicine, University of Ulsan, 388-1 Pungnap-2 Dong, SongPa-Gu, Seoul 138-736, Korea. 3. Cancer Cell and Molecular Biology Branch, Research Institute, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 410-769, Korea. 4. Department of Medical Oncology & Hematology, Kyung Hee Medical Center, Kyung Hee University, Seoul 130-702, Korea. 5. Cancer Biostatics Branch, Research Institute, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 410-769, Korea. 6. Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, College of Medicine, University of Ulsan, 388-1 Pungnap-2 Dong, SongPa-Gu, Seoul 138-736, Korea.

**Authors’ contributions**

CCM and SJJ made the tissue microarrays, analyzed the immunohistochemical staining data, collected the clinical data and contributed to the writing of the manuscript. SYP, DSK and KSP performed the cell culture, in vitro invasion and migration assays. SYP, DSK and HKR performed immunohistochemical staining. JHH and HYK analyzed the statistical data. SYK participated in designing the study and in writing the manuscript. KMH participated in designing and coordinating the study, and in writing the manuscript. All of the authors read and approved the final manuscript. KTORG supported this project as one of the collaborative projects.

**Competing interests**

The authors declare that they have no competing interests.

Received: 29 March 2011 Accepted: 24 September 2011
Published: 24 September 2011

**References**

1. Kim HS, Park K, Jun HL, Yi SY, Lee J, Ahn JS, Park YH, Kim S, Lee S, Ahn MJ: Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras. Oncology 2009, 76:239-246.

2. Coate LE, Leighl NB: How Affordable are Targeted Therapies in Non-Small Cell Lung Cancer? Curr Treat Options Oncol 2011.
3. Scaglotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L, Shepherd FA. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009, 14:253-263.

4. Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nature Reviews Molecular Cell Biology 2003, 4:140-156.

5. Han JA, Park SC. Reduction of transglutaminase 2 expression is associated with an induction of drug sensitivity in the PC-14 human lung cancer cell line. J Cancer Res Clin Oncol 1999, 125:89-95.

6. Cao L, Petrusca DN, Satpathy M, Nakshatri H, Petracek J, Matei D. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis 2008, 29:1893-1900.

7. Mehta K. High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells. International journal of cancer 1994, 58:400-406.

8. Mehta K, Fok J, Miller FR, Koul D, Sahin A. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clinical cancer research 2004, 10:8068-8076.

9. Park KS, Kim HK, Lee JH, Choi YB, Park SY, Yang SH, Kim SY, Hong KM. Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer. J Cancer Res Clin Oncol 2010, 136:693-702.

10. Antonyjak EA, Li B, Regan AD, Feng Q, Dusabain SS, Cerione RA. Tissue transglutaminase is an essential participant in the epidermal growth factor-stimulated signaling pathway leading to cancer cell migration and invasion. J Biol Chem 2009, 284:17914-17925.

11. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Frierman DJ, Vivas-Mejia PE, Deavers MT, et al. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res 2008, 68:5889-5898.

12. Mangala LS, Fok JY, Zorilla-Calancha IR, Verma A, Mehta K. Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 2007, 26:2459-2470.

13. Satpathy M, Cao L, Pinchera R, Emerson R, Bigsby R, Nakshatri H, Matei D. Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Res 2007, 67:7194-7202.

14. Chen SH, Lin CY, Lee LT, Chang GD, Lee PP, Hung CC, Kao WT, Tsai PH, Schally AV, Hwang JJ, Lee MT. Up-regulation of fibronectin and tissue transglutaminase promotes cell invasion involving increased association with integrin and MMP expression in A431 cells. Anticancer Res 2008, 30:4177-4186.

15. Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 2010, 5:442-447.

16. Jeong JM, Murthy SN, Radek JT, Lorand L. The fibronectin-binding domain of transglutaminase. J Biol Chem 1995, 270:5654-5658.

17. Hwang J, Zemskov EA, Lorand L, Belkin AM. Identification of a novel recognition sequence for fibronectin within the NH2-terminal sandwich domain of tissue transglutaminase. J Biol Chem 2005, 280:23675-23683.

18. Janiak A, Zemskov EA, Belkin AM. Cell surface transglutaminase promotes RhoA activation via integrin clustering and suppression of the Src-p190RhoGAP signaling pathway. Mol Biol Cell 2006, 17:1606-1619.

19. Lipscomb EA, Mercurio AM. Mobilization and activation of a signaling competent alpha6beta1integrin underlies its contribution to carcinoma progression. Cancer Metastasis Rev 2005, 24:413-423.

20. Kumar A, Xu J, Brady S, Gao H, Yu D, Reuben J, Mehta K. Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One 2010, 5:e13390.

21. Kim D, Park S, Nam B, Kim I, Kim S. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer research 2006, 66:10936-10943.

22. Mann AP, Verma A, Seth G, Manavathu B, Wang H, Fok JY, Kunnumakkara AB, Kumar R, Aggarwal B, Mehta K. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer research 2006, 66:8788-8795.

Cite this article as: Choi et al. Transglutaminase 2 as an independent prognostic marker for survival of patients with non-adenocarcinoma subtype of non-small cell lung cancer. Molecular Cancer 2011 10:119.